Please use this identifier to cite or link to this item:
|Title:||Nox-4 and progressive kidney disease.|
|Authors:||Thallas-Bonke, Vicki;Jandeleit-Dahm, Karin A M;Cooper, Mark E|
|Affiliation:||aDiabetes Complications Division, Baker IDI Heart & Diabetes Institute, JDRF Danielle Alberti Memorial Centre for Diabetic Complications bDepartment of Medicine, Austin and Northern Clinical Schools, University of Melbourne cDepartment of Medicine, Central Clinical School, Monash University, AMREP Precinct, Melbourne, Victoria, Australia.|
|Citation:||Current Opinion in Nephrology and Hypertension; 24(1): 74-80|
|Abstract:||Nox-4 is a member of the NADPH oxidase (Nox) family of enzymes implicated in reactive oxygen species generation. Nox-4 is distributed in many tissues; however, its physiological functions remain poorly understood. In contrast to other Nox isoforms, it is unique in that it produces large amounts of hydrogen peroxide constitutively and does not require other cytosolic oxidase components for its activation. This review highlights the recent developments in Nox-4 research and progressive kidney disease as well as the potential of new Nox-4 inhibitors to reduce renal damage.Recently, Nox-4 was shown to be implicated in kidney diseases such as diabetic nephropathy. Nox-4 has been identified as playing a role in damage to the kidney induced by hyperglycaemia and other major pathways of renal damage, including advanced glycation end-products, the renin-angiotensin system, TGF-β and protein kinase C.The role of Nox-4 as a target for renoprotection remains controversial, although recent positive preclinical data have stimulated increased interest in inhibiting the enzyme in clinical trials of renal disease.|
|Internal ID Number:||25402870|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.